middle.news
Actinogen Medical Advances Alzheimer's Drug with Pivotal Trial Results Due November
4:26pm on Thursday 27th of August, 2026 AEST
•
Healthcare
Read Story
Actinogen Medical Advances Alzheimer's Drug with Pivotal Trial Results Due November
4:26pm on Thursday 27th of August, 2026 AEST
Key Points
FY2026 net loss of $15.38 million
XanaMIA Alzheimer's trial fully enrolled with topline results due November
Open-label extension phase launched with 89% participant rollover
Regulatory alignment achieved with FDA and EMA for streamlined approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE